12 Health Care Stocks Moving In Friday's Intraday Session

Benzinga · 6h ago
Gainers
- Pulse Biosciences (NASDAQ:PLSE) shares increased by 45.3% to $19.89 during Friday's regular session. The company's market cap stands at $927.7 million.
- Vyome Holdings (NASDAQ:HIND) stock rose 24.34% to $2.86. The company's market cap stands at $12.9 million.
- TuHURA Biosciences (NASDAQ:HURA) shares rose 22.28% to $0.54. The market value of their outstanding shares is at $24.8 million.
- BNB Plus (NASDAQ:BNBX) shares increased by 22.22% to $1.05. The company's market cap stands at $3.7 million.
- Bio Green Med Solution (NASDAQ:BGMS) stock moved upwards by 21.6% to $1.01. The company's market cap stands at $4.0 million.
- Ginkgo Bioworks Holdings (NYSE:DNA) stock rose 21.26% to $10.09. The company's market cap stands at $504.1 million.
Losers
- Ernexa Therapeutics (NASDAQ:ERNA) shares decreased by 51.8% to $0.33 during Friday's regular session. The market value of their outstanding shares is at $5.3 million.
- Anebulo Pharmaceuticals (NASDAQ:ANEB) stock declined by 36.06% to $0.53. The company's market cap stands at $33.4 million.
- Molina Healthcare (NYSE:MOH) stock fell 27.69% to $127.88. The market value of their outstanding shares is at $9.0 billion. As per the news, the Q4 earnings report came out yesterday.
- Estrella Immunopharma (NASDAQ:ESLA) stock fell 25.63% to $0.98. The company's market cap stands at $49.8 million.
- Doximity (NYSE:DOCS) stock declined by 25.19% to $24.93. The company's market cap stands at $6.2 billion. As per the news, the Q3 earnings report came out yesterday.
- Agape ATP (NASDAQ:ATPC) shares declined by 21.27% to $0.05. The market value of their outstanding shares is at $3.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.